J&A advised Fira Nord-Est, a seed fund managed by Finovam Gestion, on StemInov’s €10.6 million fundraising.
Joffe & Associés advised Fira Nord-Est, a seed fund managed by Finovam Gestion, on StemInov’s €10.6 million fundraising.
This French biopharmaceutical company develops innovative cell therapies for the treatment of inflammatory and autoimmune diseases.
The transaction will enable StemInov to accelerate its industrial and clinical development.
The funds raised will support the implementation of a bioproduction platform compliant with European regulatory standards, facilitating the necessary approvals for the commercialization of its therapies.
The Joffe & Associés team advising on this transaction included Thomas Saltiel, partner, and Charlotte Viandaz, counsel.
